AstraZeneca shares seen rising after 3Q beat, J.P. Morgan says

AstraZeneca's third-quarter results beat expectations on the top and bottom lines, and the company reiterated its 2026 and 2030 guidance. J.P. Morgan analysts expect the shares to outperform by at least 2-3% on Friday, citing strong sales across oncology, rare disease, vaccines, and respiratory and immunology segments, which offset a weaker cardiovascular, renal, and metabolism performance.